Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the GLP-1 Receptor Agonist Market Heading Into 2029?
Over the past few years, the GLP-1 receptor agonist market has witnessed consistent growth. It is projected to increase from $13.58 billion in 2024 to $14.09 billion in 2025, boasting a compound annual growth rate (CAGR) of 3.8%. Factors contributing to the growth in the historic period include heightened diabetes occurrence, clinical effectiveness, patient understanding and approval, worldwide health initiatives, and the patient inclination towards injectable treatments.
The market size of GLP-1 receptor agonist is projected to witness substantial expansion in the coming years. The size is anticipated to reach “$17.36 billion in 2029, growing at a CAGR of 5.4%. The surge in the projected period can be accredited to the rising focus on lifestyle modification, the increase in personalized medicine methods, the broadening of indications, the inception of newer generation products, and integration with combination therapies. Major trends predicted during the projection period comprise the launch of oral formulations, emphasis on combination therapies, strategic alliances and partnerships, reimbursement policies and accessibility, and patient-focused approaches.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp
Which Factors Are Pushing The GLP-1 Receptor Agonist Market Forward?
The growing incidence of diabetes is likely to spur the GLP-1 receptor agonist market’s advancement. Diabetes, a chronic disease, arises when either the pancreas fails to produce enough insulin, or the body is unable to make efficient use of the insulin it produces. Elevated sugar levels in the blood signify the metabolic disorder known as diabetes mellitus. GLP-1 receptor agonist, employed in diabetes treatment, stimulates the body to generate more insulin, which in turn regulates the blood sugar levels. This increasing incidence of diabetes is predicted to fuel market growth. For instance, from March 2022 to March 2023, the UK’s Office for Health Improvement and Disparities reported a 22% increase in the proportion of type 1 diabetes patients receiving all eight recommended care processes. Likewise, the number went up by 21% for type 2 diabetes patients. Additionally, the percentage of patients achieving target HbA1c levels surged to a record 37.9%, as per the National Diabetes Audit (NDA). Consequently, the escalating prevalence of diabetes is steering the growth of the GLP-1 receptor agonist market.
Which Segment Held The Largest Share In The GLP-1 Receptor Agonist Market In 2025?
The glp-1 receptor agonist market covered in this report is segmented –
1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users
Subsegments:
1) By Exenatide: Byetta, Bydureon
2) By Liraglutide: Victoza, Saxenda
3) By Dulaglutide: Trulicity
4) By Lixisenatide: Adlyxin
5) By Other Drugs: Semaglutide, Tirzepatide, Others
What Trends Are Currently Influencing Growth In The GLP-1 Receptor Agonist Market?
One key trend emerging in the GLP-1 receptor agonist market is product innovation. Leading companies within this market are concentrating on the development of novel solutions to bolster their standing. As an illustration, the FDA approved a new product, Mounjaro, a GIP and GLP-1 receptor agonist, launched by Eli Lilly and Company, a U.S. pharmaceutical firm devoted to improving lives through medicine, in May 2022. Specifically, this product is engineered from a single molecule which activates the body’s receptors for the incretin hormones GIP and GLP-1. It is provided in a pre-attached, concealed needle pen auto-injector, removing the need for patients to handle or view the needle, and is available in 6 different doses.
Which Organizations Are Driving Progress In The GLP-1 Receptor Agonist Industry?
Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report
Which Region Is Expected To Experience The Highest Growth In The GLP-1 Receptor Agonist Industry?
North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the GLP-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9631&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
